Integrated Filing — IndAS


General information about company

Scrip Code 540145
NSE Symbol VALIANTORG
MSEI Symbol NOTLISTED
ISIN INE565V01010
Name of company Valiant Organics Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 22-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Chemical
Start date and time of board meeting 22-May-2025   14:00:00
End date and time of board meeting 22-May-2025   18:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-13
Indicate Company website link for updated RPT policy of the Company https://www.valiantorganics.com/assets/investors/related-party-transactions-policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The dislosure for the default on loans and debts securities is not applicable to the entity



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2038119000 7187618000
Other income 6674000 81127000
Total income 2044793000 7268745000
2 Expenses
(a) Cost of materials consumed 1370289000 4400701000
(b) Purchases of stock-in-trade 8196000 126156000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -54158000 44552000
(d) Employee benefit expense 107594000 449889000
(e) Finance costs 46542000 236388000
(f) Depreciation, depletion and amortisation expense 92004000 357604000
(f) Other Expenses
1 Other Expenses 403278000 1629356000
Total other expenses 403278000 1629356000
Total expenses 1973745000 7244646000
3 Total profit before exceptional items and tax 71048000 24099000
4 Exceptional items 0 0
5 Total profit before tax 71048000 24099000
6 Tax expense
7 Current tax 0 0
8 Deferred tax 31487000 54083000
9 Total tax expenses 31487000 54083000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 39561000 -29984000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 39561000 -29984000
17 Other comprehensive income net of taxes -4317000 -9270000
18 Total Comprehensive Income for the period 35244000 -39254000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 280046000 280046000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 6336089000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.43 -1.09
Diluted earnings (loss) per share from continuing operations 1.43 -1.09
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.43 -1.09
Diluted earnings (loss) per share from continuing and discontinued operations 1.43 -1.09
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 6440392000
Capital work-in-progress 656971000
Investment property 0
Goodwill 0
Other intangible assets 4545000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 540793000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 56799000
Total non-current financial assets 597592000
Deferred tax assets (net) 0
Other non-current assets 50877000
Total non-current assets 7750377000
2 Current assets
Inventories 889712000
Current financial asset
Current investments 0
Trade receivables, current 1742281000
Cash and cash equivalents 70648000
Bank balance other than cash and cash equivalents 3687000
Loans, current 5696000
Other current financial assets 55000000
Total current financial assets 1877312000
Current tax assets (net) 119380000
Other current assets 156377000
Total current assets 3042781000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 10793158000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 280046000
Other equity 6336089000
Total equity attributable to owners of parent 6616135000
Non controlling interest
Total equity 6616135000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 506910000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 15394000
Total non-current financial liabilities 522304000
Provisions, non-current 21997000
Deferred tax liabilities (net) 343932000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 888233000
Current liabilities
Current financial liabilities
Borrowings, current 1606659000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 78397000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1381793000
Total Trade payable 1460190000
Other current financial liabilities 158072000
Total current financial liabilities 3224921000
Other current liabilities 16847000
Provisions, current 47022000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 3288790000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 4177023000
Total equity and liabilites 10793158000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit Liabiliy/Assets, net of Taxes -1173000 -1173000
2 Fair value changes on Investments, net of Taxes -3144000 -8097000
Total Amount of items that will not be reclassified to profit and loss -4317000 -9270000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -4317000 -9270000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 24099000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 236388000
Adjustments for decrease (increase) in inventories 252612000
Adjustments for decrease (increase) in trade receivables, current 351341000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -4305000
Adjustments for decrease (increase) in other non-current assets 3706000
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current -2185000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -614261000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -5137000
Adjustments for increase (decrease) in other non-current liabilities -1681000
Adjustments for depreciation and amortisation expense 357604000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 13639000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current -1546000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -780000
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -8513000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 6359000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 583241000
Net cash flows from (used in) operations 607340000
Dividends received -54000
Interest paid 0
Interest received -21686000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 585600000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities -908000
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 15129000
Purchase of property, plant and equipment 308292000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 54000
Interest received 21686000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -99000
Net cash flows from (used in) investing activities -270614000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 240000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 196311000
Repayments of borrowings 234699000
Payments of lease liabilities 1936000
Dividends paid 0
Interest paid 236388000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -276472000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 38514000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 38514000
Cash and cash equivalents cash flow statement at beginning of period 32134000
Cash and cash equivalents cash flow statement at end of period 70648000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Gokhale and Sathe Chartered Accountants Yes 28-Feb-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Valiant organics limited Shanti Intermediates Pvt Ltd Private Company having a Common Director Sale of goods or services 300000000 Approved 17725000 3459000 3162000
2 Valiant organics limited Valiant Laboratries Limited Associate Company Sale of goods or services 6000000000 Approved 420925000 -9181000 -100000
3 Valiant organics limited Aarti Drugs Limited Promoter Group Sale of goods or services 450000000 Approved 73175000 28081000 24384000
4 Valiant organics limited Aarti Pharmalabs Limited Promoter Group Sale of goods or services 700000000 Approved 341039000 0 0
5 Valiant organics limited Aarti Pharmalabs Limited Promoter Group Purchase of goods or services 500000000 Approved 102809000 86348000 -28944000
6 Valiant organics limited Ganesh Polychem Limited Promoter Group Purchase of goods or services 300000000 Approved 48312000 -19749000 -13966000
7 Valiant organics limited Dilesh Logistics India Private Limited Promoter Group Purchase of goods or services 100000000 Approved 789000 -1262000 0
8 Valiant organics limited Dinesh dyestuff Industries Partnership Firm in which Director is Partner Any other transaction Rent paid 1000000 Approved 424000 0 0
9 Valiant organics limited Dinesh dyestuff Industries Partnership Firm in which Director is Partner Purchase of fixed assets 20000000 Approved 3827000 -9462000 -9577000
10 Valiant organics limited Alchemie FinchemnPrivate Limited (AlchemienLaboratories) Promoter Group Sale of goods or services 100000000 Approved 898000 3501000 898000
11 Valiant organics limited Valiant Advance sciences Private Limited Wholly Owned Subsidiary of Valiant Laboratories Limited Sale of goods or services 50000000 Approved 2061000 0 2061000
12 Valiant organics limited Mr. Dinesh Shah Relative of Director Any other transaction Professional Fees 1500000 Approved 750000 -113000 -113000
13 Valiant organics limited Mr. Mahesh Savadia Relative of Director Any other transaction Professional Fees 1500000 Approved 737000 -109000 -110000
14 Valiant organics limited Mr.Siddharth D. Shah Executive Director Any other transaction Remuneration NA 1333000 -161000 0
15 Valiant organics limited Mr.Nemin M. Savadia Executive Director Any other transaction Remuneration NA 1208000 -128000 0
16 Valiant organics limited Mr. Mahek Chheda Executive Director Any other transaction Remuneration NA 1344000 -154000 0
17 Valiant organics limited Mr. PARIMAL DESAI Executive Director Any other transaction Remuneration NA 3000000 0 0
18 Valiant organics limited Mr. Kaustubh Kulkarni Company Secretary Any other transaction Remuneration NA 658000 -104000 -91000
19 Valiant organics limited Mr. SUDHIRPRAKASH BABURAO SAWANT Non Executive Director Any other transaction Sitting Fees NA 65000 0 0
20 Valiant organics limited Mr. NAVIN SHAH Non Executive Director Any other transaction Sitting Fees NA 100000 0 0
21 Valiant organics limited Mr. SONAL VIRA Non Executive Director Any other transaction Sitting Fees NA 65000 0 0
22 Valiant organics limited Mr. SANTOSH VORA Non Executive Director Any other transaction Sitting Fees NA 38000 0 0
23 Valiant organics limited Mr.Mulesh Savla Non Executive Director Any other transaction Sitting Fees NA 118000 0 0
24 Valiant organics limited Mr. PARIMAL DESAI Non Executive Director Any other transaction Sitting Fees NA 28000 0 0
25 Valiant organics limited Mr. Paras Savla Non Executive Director Any other transaction Sitting Fees NA 20000 0 0
26 Valiant organics limited Gratutiy Trust -Valiant/ Amarjyot/ Abhilasha Gratuity Trust Any other transaction Payment to LIC NA 1028000 30823000 32745000
27 Valiant organics limited Dhanvallabh Ventures LLP Ultimate Holding of Valiant Organics Limited Investment 200000000 NA -58000 0 495058000
28 Valiant organics limited Valiant Specialty Chemicals Limited Ultimate Holding of Valiant Organics Limited Investment NA 0 2500000 2500000
29 Valiant organics limited Aarti Surfactants Limited Promoter Group Purchase of goods or services 10000000 NA 0 5000 0
30 Valiant organics limited Aarti Industries Limited Promoter Group Sale of goods or services 2500000000 Approved 604574000 0 0
31 Valiant organics limited Aarti Industries Limited Promoter Group Purchase of goods or services 7000000000 Approved 1651158000 -1515672000 -1166151000
32 Valiant organics limited Aarti Industries Limited Promoter Group Any other transaction Interest Payable Approved 82000000 0 0
33 Valiant organics limited Alchemie Speciality Chemicals Private Limited Private Company having a Common Director Sale of goods or services 600000000 Approved 184963000 265578000 209921000
34 Valiant organics limited Alchemie Speciality Chemicals Private Limited Private Company having a Common Director Purchase of goods or services 600000000 Approved 1356000 0 0
35 Valiant organics limited Alchemie Speciality Chemicals Private Limited Private Company having a Common Director Any other transaction Rent Received 1500000 Approved 708000 0 0
36 Valiant organics limited Alchemie Speciality Chemicals Private Limited Private Company having a Common Director Any other transaction Interest Receivable NA 20974000 0 0
37 Valiant organics limited Mr. Sathiababu Kallada Executive Director Remuneration NA 1749000 0 0
38 Valiant organics limited Mr. Sathiababu Kallada Executive Director Any other transaction ESOP Perquisites NA 4603000 0 0
39 Valiant organics limited DR KIRITKUMAR DESAI Non Executive Director Any other transaction Sitting Fees NA 30000 0 0
40 Valiant organics limited DR KIRITKUMAR DESAI Non Executive Director Any other transaction ESOP Perquisites NA 4791000 0 0
41 Valiant organics limited Valiant Laboratries Limited Associate Company Sale of fixed assets NA 413000 0 0
42 Valiant organics limited Mr. PARIMAL DESAI Executive Director Any other transaction Commission NA 742000 0 -742000
43 Valiant Laboratories Limited Shantilal Vora Non Executive Director Loan NA 0 -35894000 -35894000
44 Valiant Laboratories Limited Paresh Shah Executive Director(CFO) Remuneration NA 750000 0 0
45 Valiant Laboratories Limited Paresh Shah Executive Director(CFO) Loan NA 0 -35943000 -35943000
46 Valiant Laboratories Limited Valiant Advanced Sciences Private Limited Wholly Owned Subsidiary Investment NA 0 1650580000 1650580000
47 Valiant Laboratories Limited Valiant Advanced Sciences Private Limited Wholly Owned Subsidiary Sale of fixed assets NA 489000 168000 657000
48 Valiant Laboratories Limited Valiant Advanced Sciences Private Limited Wholly Owned Subsidiary Any other transaction Reimbursement of remuneration 10000000 Approved 600000 0 600000
49 Valiant Laboratories Limited Valiant Advanced Sciences Private Limited Wholly Owned Subsidiary Advance NA -14099000 32965000 18896000 Advance 0 NA Unsecured For the purpose of business
50 Valiant Laboratories Limited Valiant Advanced Sciences Private Limited Wholly Owned Subsidiary Purchase of goods or services 2000000000 Approved -21000 0 -21000
51 Valiant Laboratories Limited Dhanvallabh Ventures LLP Holding Company Loan NA 0 -486161000 -486161000
52 Valiant Laboratories Limited Prajakta Patil Company Secretary Remuneration NA 733000 0 0
53 Valiant Laboratories Limited Aarti Pharmalabs Limited Other Related Party Any other transaction Rent Received 50000000 Approved 17700000 0 2700000
54 Valiant Laboratories Limited Aarti Pharmalabs Limited Other Related Party Purchase of goods or services 70000000 Approved 20761000 -2951000 0
55 Valiant Laboratories Limited Aarti Pharmalabs Limited Other Related Party Any other transaction Deposit Received 20000000 Approved 0 -9614000 -9614000
56 Valiant Laboratories Limited Aarti Pharmalabs Limited Other Related Party Any other transaction Other Reimbursements 100000000 Approved 31786000 16609000 4576000
57 Valiant Laboratories Limited The Trust Valiant Laboratories Limited Gratuity Trust Any other transaction Gratuity Premium NA 234000 0 0
58 Valiant Laboratories Limited Rachi Vora Promoter Group Remuneration NA 750000 0 0
59 Valiant Laboratories Limited Santosh Vora Executive Director(MD) Remuneration NA 600000 0 0
60 Valiant Laboratories Limited Santosh Vora Executive Director(MD) Loan NA 0 -36003000 -36003000
61 Valiant Advanced Sciences Private Limited J.B.Singh Executive Director Remuneration NA 700000 0 0
Total value of transaction during the reporting period 3641462000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt